Upgrades aim to improve asthma relief and COPD treatment with advanced technology.United States, January 31, 2025 -- TruNeb ...
If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...
Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...
In a world where respiratory issues are increasingly common, finding practical solutions can be daunting. Breathe Drops ...
Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...
Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
In today’s fast-paced world, respiratory issues have become increasingly common, affecting individuals of all ages. Whether it’s due to environmental pollutants, allergens, or chronic conditions like ...
COPD-asthma-devices-market2025 PORTLAND, DE, UNITED STATES, January 29, 2025 /EINPresswire / -- Day-to-day exposure to environmental pollutio ...
Breathing is essential for life, yet for many individuals suffering from chronic respiratory issues such as asthma and COPD, ...
It has been found in a recent study published in Heliyon that individuals who are genetically predisposed to having ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback